Headlines about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.129065047236 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several research firms recently commented on APEN. ValuEngine cut shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Roth Capital began coverage on shares of Apollo Endosurgery in a research note on Wednesday, August 2nd. They set a “buy” rating and a $10.00 target price for the company. Finally, Craig Hallum began coverage on shares of Apollo Endosurgery in a research note on Monday, July 24th. They set a “buy” rating and a $11.00 target price for the company.
Apollo Endosurgery (APEN) traded up 1.78% during trading on Tuesday, reaching $4.57. 3,723 shares of the company traded hands. Apollo Endosurgery has a 12 month low of $2.00 and a 12 month high of $21.88. The company’s 50-day moving average is $4.64 and its 200 day moving average is $7.52. The company’s market cap is $78.84 million.
Apollo Endosurgery (NASDAQ:APEN) last announced its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.40). Apollo Endosurgery had a negative net margin of 81.59% and a negative return on equity of 142.98%. The business had revenue of $17.14 million for the quarter. On average, analysts anticipate that Apollo Endosurgery will post ($2.18) earnings per share for the current year.
In other Apollo Endosurgery news, major shareholder Holdings A/S Novo sold 50,130 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $6.90, for a total transaction of $345,897.00. Following the completion of the sale, the insider now owns 1,334,772 shares of the company’s stock, valued at approximately $9,209,926.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Todd Newton purchased 136,363 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were acquired at an average cost of $5.50 per share, with a total value of $749,996.50. Following the acquisition, the chief executive officer now directly owns 167,129 shares in the company, valued at $919,209.50. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,277,271 shares of company stock valued at $7,024,991 in the last ninety days. Insiders own 74.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Apollo Endosurgery (APEN) Receives Daily Media Sentiment Score of 0.14” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/apollo-endosurgery-apen-receives-daily-media-sentiment-score-of-0-14.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.